ILMN - Rasio rega marang prakiraan pendapatan Illumina Platform

Logo grafis Illumina, Inc. (ILMN)

The forward P/S ratio of Illumina, Inc. (ILMN) correlates with the operations of sterile plants in Singapore, the US, and the UK. The implementation of autonomous robotic biomaterial analyzers optimizes processes, while the 6.60 mark indicates the level of market expectations. The business relies on its monopoly in DNA sequencing, generating revenue through the recurring sale of high-cost reagents for mass diagnostics.

ILMN (Illumina) riwayat Multiplikator Forward P/S saka 04.07.2022 nganti 15.11.2026

Rincian analitis perusahaan Illumina, Inc.

- rega pasar lan target rega analis:
Pambiji fundamental perusahaan:Illumina Inc ILMN
Sampel barang Illumina, Inc.

For Illumina, Inc. (ILMN), which is protected by unique DNA sequencing patents, the forward P/S ratio serves as an indicator of revenue resilience in the face of regulatory pressure. This metric compares current market value with expected sales, making it possible to identify systemic business degradation behind the apparent cheapness of the asset. The 6.60 value on the chart determines the extent to which the market is willing to pay a premium for future growth amid stringent antitrust restrictions.

Pesaing Illumina, Inc.

Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Exact Sciences Inc. - Multiplikator Forward P/S|RVTY: Rasio rega marang prakiraan pendapatan|Bio-Rad (BIO) - Rasio rega marang prakiraan pendapatan|NNNN - Rasio kapitalisasi marang dodolan sing dikarepake|SHC (Sotera Health Corp) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep QuidelOrtho Inc. QDEL|Multiplikator Forward P/S OPK|CareDx - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S MRVI (Maravai LifeSciences Holdings)|Rasio rega marang pendapatan sing dikarepake FLGT (Fulgent Corp)|LAB: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Multiplikator forward rega marang pendapatan|Multiplikator forward rega marang pendapatan Exagen Inc.|Multiplikator forward rega marang pendapatan MDXH|LUCD - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Prenetics (PRE)|Rasio rega marang prakiraan pendapatan IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Multiplikator forward rega marang pendapatan|prophaselabs.com - Rasio rega marang prakiraan pendapatan|AIMD - Rasio rega marang prakiraan pendapatan|Co-Diagnostics Inc (CODX) - Multiplikator forward rega marang pendapatan|HSCS: Multiplikator Forward P/S|BMRA - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CDIO|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep onconetix.gcs-web.com ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs (VRAX)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc